According to Sunflower Pharmaceutical's announcement, the company used 400 million yuan of idle capital to purchase fixed income floating income wealth management products, involving China Merchants Bank, Industrial Bank, Shanghai Pudong Development Bank, and China CITIC Bank related products. Among them, SPDB Wealth Management Zhou Zhou of the Harbin Branch Sales Department of Shanghai Pudong Development Bank held 100 million yuan for a minimum period of 100 million yuan. The performance comparison benchmark was 2.0%. The starting date was September 18, 2026. As of the announcement date, the unexpired amount of the company's cash management was 1,580 billion yuan.

According to Sunflower Pharmaceutical's announcement, the company used 400 million yuan of idle capital to purchase fixed income floating income wealth management products, involving China Merchants Bank, Industrial Bank, Shanghai Pudong Development Bank, and China CITIC Bank related products. Among them, SPDB Wealth Management Zhou Zhou of the Harbin Branch Sales Department of Shanghai Pudong Development Bank held 100 million yuan for a minimum period of 100 million yuan. The performance comparison benchmark was 2.0%. The starting date was September 18, 2026. As of the announcement date, the unexpired amount of the company's cash management was 1,580 billion yuan.